Peregrine (PPHM) storms 15.6% higher after its bavituximab treatment performed well in a Phase...

|By:, SA News Editor

Peregrine (PPHM) storms 15.6% higher after its bavituximab treatment performed well in a Phase II trial of 70 patients with advanced Stage IV pancreatic cancer. In combination with the gemcitabine chemotherapy, overall tumor response rates were 28% vs 13% with gemcitabine alone. (PR)